Table 4 Cytokines and coagulation parameters in 73 COVID-19 patients stratified according to high (≥ median) versus low (< median) MCP-1
From: IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19
Total (N = 73) | MCP-1 | P | |||||
|---|---|---|---|---|---|---|---|
Low (N = 27) | High (N = 46) | ||||||
n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | ||
IL-1β, pg/mL | 29 | 5.0 (5.0–5.0) | 8 | 5.0 (5.0–5.0) | 21 | 5.0 (5.0–5.9) | 0.491 |
IL-2R, U/mL | 29 | 1059.0 (460.0–1642.0) | 8 | 1075.0 (382.0–1674.5) | 21 | 1059.0 (518.5–1754.0) | 0.391 |
IL-6, pg/mL | 48 | 74.2 (17.0–157.5) | 20 | 19.1 (8.7–93.1) | 28 | 114.3 (38.2–353.1) | 0.001 |
IL-8, pg/mL | 29 | 51.7 (12.5–114.7) | 8 | 20.3 (10.6–30.6) | 21 | 77.0 (16.2–163.0) | 0.064 |
IL-10, pg/mL | 29 | 11.4 (5.0–20.1) | 8 | 5.0 (5.0–16.4) | 21 | 11.7 (5.4–31.6) | 0.095 |
TNFα, pg/mL | 27 | 12.7 (7.5–28.7) | 8 | 8.6 (6.4–13.8) | 19 | 13.3 (7.9–30.5) | 0.27 |
Prothrombin time (PT), s | 71 | 15.9 (14.9–18.2) | 26 | 15.0 (14.2–16.1) | 45 | 17.0 (15.6–19.0) | 0.001 |
Prothrombin activity (PTA), % | 71 | 69.0 (55.0–80.0) | 26 | 77.5 (68.3–88.0) | 45 | 62.0 (51.0–71.5) | 0.001 |
International normalized ratio (INR) | 71 | 1.26 (1.15–1.49) | 26 | 1.17 (1.09–1.28) | 45 | 1.37 (1.23–1.58) | 0.001 |
Fibrinogen (FIB), g/L | 71 | 4.2 (3.1–5.2) | 26 | 4.1 (3.4–5.1) | 45 | 4.4 (3.0–5.3) | 0.878 |
Activated partial thromboplastin time (APTT), s | 71 | 44.5 (39.3–52.6) | 26 | 43.3 (37.9–50.6) | 45 | 45.4 (40.0–56.1) | 0.228 |
Thrombin time (TT), s | 71 | 15.3 (14.5–16.5) | 26 | 15.2 (14.5–16.1) | 45 | 15.4 (14.6–17.6) | 0.316 |
d-dimer, μg/mL FEU | 71 | 3.85 (1.68–13.46) | 26 | 2.03 (1.25–5.48) | 45 | 6.30 (2.52–15.76) | 0.005 |
Fibrin degradation products (FDP), μg/mL | 30 | 17.2 (6.2–68.6) | 9 | 5.7 (4.0–38.7) | 21 | 32.6 (13.6–130.5) | 0.019 |
Antithrombin (AT), % | 34 | 80.5 (65.5–88.5) | 11 | 84.0 (78.0–93.0) | 23 | 75.0 (60.0–86.0) | 0.12 |